LONDON, UK / ACCESSWIRE / May 15, 2018 / If you want access to our free research report on RXi Pharma Corp. (NASDAQ: RXII), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=RXII as the Company's latest news hit the wire. On May 11, 2018, the Company announced that it has inked a research collaboration deal with Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance") to evaluate the potential synergies with RXi's novel sd-rxRNA therapeutic compounds and Iovance's autologous cell therapy based on tumor-infiltrating lymphocytes (TILs), for use in the treatment of cancer. The financial terms of the transaction remained undisclosed. Register today and get access to over 1,000 Free Research Reports by joining our site below:
Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, RXi Pharma and Iovance Biotherapeutics most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:
RXi will Further Investigate and Expand Recently Published Data with TIL and Sd-rxRNA Products
Commenting on the announcement, Dr. Geert Cauwenbergh, President and Chief Executive Officer (CEO) of RXi, stated that the agreement will allow Iovance to explore their proprietary TIL technology and RXi's proprietary sd-rxRNA technology. Under this research collaboration, RXi will further investigate and expand the recently published data with TIL and sd-rxRNA products, which demonstrated the potentially enhanced tumor killing activity of TIL. Dr. Cauwenbergh added that as such, the Company may be able to improve the potency of the TIL product and also possibly broaden the applicability of TIL in other tumors types.
News reports suggest that post announcement of the news, RXi's shares surged in pre-market trade.
RXi and Gustave Roussy Research Collaboration
On November 13, 2017, RXi and Gustave Roussy, which is a leading Comprehensive Cancer Centre in Europe, entered into a collaborative research agreement to evaluate the potential of RXi's novel sd-rxRNA technology platform for use in cancer treatments. The agreement covered research to design and evaluate sd-rxRNA compounds in a human tumor xenograft model. Positive results might lead to further development of these compounds for the treatment of cancer. RXi's sd-rxRNA technology platform is broadly applicable to many therapeutic areas, including cancer.
RXI Announced Publication in Molecular Therapy on Sd-rxRNA® Targeting PD-1 in Adoptive Cell Therapy
On April 16, 2018, the Company announced that research conducted using its self-delivering RNAi platform in the field of immunotherapy to treat cancer was published in a leading peer-reviewed journal. The paper described research done to evaluate the potential of improving TIL therapy by applying RXi's novel sd-rxRNA compounds specific to PD-1. The results showed that targeting the PD-1/PD-L1 axis could enhance the ex-vivo expansion rate and in-vivo longevity of patient derived TILs used for ACT in malignant melanoma patients. Transfection of these T-cells with the PD-1 targeting self-delivering sd-rxRNA compounds was easy to incorporate in an established, clinically-relevant rapid expansion protocol, and resulted in increased functionality of the transfected TILs against autologous tumors compared to control TIL.
About Iovance Biotherapeutics, Inc.
Headquartered in San Carlos, California, Iovance Biotherapeutics is focused on the development and commercialization of autologous cellular immunotherapies optimizing personalized, tumor-directed TIL. Iovance is conducting three Phase-2 clinical trials to assess the efficacy and safety of autologous TIL for the treatment of patients with Metastatic Melanoma, Squamous Cell Carcinoma of the Head and Neck, and Cervical Cancer.
About RXi Pharmaceuticals Corp.
Founded in 2011 and headquartered in Marlborough, Massachusetts, RXi is a clinical-stage Company developing innovative therapeutics that address significant unmet medical needs. RXi developed a robust RNAi therapeutic platform, including sd-rxRNA® compounds, that have the ability to highly selectively block the expression of any target in the genome, thus providing applicability to a broad spectrum of therapeutic areas.
Stock Performance Snapshot
May 14, 2018 - At Monday's closing bell, RXi Pharma's stock rose 5.04%, ending the trading session at $2.50.
Volume traded for the day: 499.58 thousand shares, which was above the 3-month average volume of 391.28 thousand shares.
After yesterday's close, RXi Pharma's market cap was at $9.03 million.
The stock is part of the Healthcare sector, categorized under the Biotechnology industry. This sector was up 0.7% at the end of the session.
Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
A-I has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.